Korean J Obstet Gynecol.  2011 Jan;54(1):17-25. 10.5468/KJOG.2011.54.1.17.

The correlation of pregnancy complications with C3/C4 levels, anti-dsDNA titers, and autoimmune target testing in gravidas with systemic lupus erythematosus

• Kim ID
• Kim RH
• Kang GU
• Jin SA
• Lee HJ
• Hoh JK
• Chang HS
• Hwang KJ
• Park MI

• KMID: 2274018
• DOI: http://doi.org/10.5468/KJOG.2011.54.1.17

Abstract

OBJECTIVE
The purpose of this study was to evaluate the correlation between complement (C3 and C4) levels, anti-dsDNA titers, autoimmune target test (AITT), and pregnancy complications.
METHODS
Ninety-three pregnancies with systemic lupus erythematosus (SLE) were analyzed retrospectively. We evaluated the course of the pregnancy and outcome, pregnancy complications, progression of SLE, maternal complications of SLE, drugs taken before and after pregnancy, neonatal outcomes, and C3/C4 levels, anti-dsDNA titers, and AITT results. SPSS ver. 14.0 was used for statistical analysis. The average and standard deviation are shown. Chi-square test and Pearson correlation test were used for statistical analysis. The significance level was set at 0.05.
RESULTS
The C3 level was associated with maternal leukopenia, elevated serum C-reactive protein (CRP) elevation, hematuria, hypertension, and preterm premature rupture of membranes. The C4 level was associated with maternal proteinuria, hematuria, hematologic disease, and admission to the neonatal intensive care unit. The anti-dsDNA titer was associated with elevated maternal serum CRP, oligohydramnios, and neonatal anti-Sjogren's syndrome B (La) antibody. The AITT result was related to elevated erythrocyte sedimentation rate, and 1 and 5 minute Apgar scores.
CONCLUSION
Our result show that adding the AITT to conventional C3/C4 and anti-dsDNA testing in gravidas with SLE might help antenatal care.

Keyword

Systemic lupus erythematosus; Anti-dsDNA; Complement (C3/C4); Autoimmune target test

MeSH Terms

Blood Sedimentation
C-Reactive Protein
Complement System Proteins
Female
Hematologic Diseases
Hematuria
Hypertension
Infant, Newborn
Intensive Care, Neonatal
Leukopenia
Lupus Erythematosus, Systemic
Membranes
Oligohydramnios
Pregnancy
Pregnancy Complications
Pregnancy Outcome
Proteinuria
Retrospective Studies
Rupture
C-Reactive Protein
Complement System Proteins

Reference

1. Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol. 2005. 32:1709–1712.

2. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol. 1998. 25:1526–1530.

3. Carmona F, Font J, Cervera R, Munoz F, Cararach V, Balasch J. Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus: a study of 60 cases. Eur J Obstet Gynecol Reprod Biol. 1999. 83:137–142.

4. Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol. 2003. 30:2127–2132.

5. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008. 199:127.e1–127.e6.

6. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 2002. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins.

7. Ruiz-Irastorza G, Khamashta MA. Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus. 2004. 13:679–682.

8. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007. 33:237–252.

9. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol. 2006. 305:67–88.

10. Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002. 41:643–650.

11. Tincani A, Spatola L, Cinquini M, Meroni P, Balestrieri G, Shoenfeld Y. Animal models of antiphospholipid syndrome. Rev Rhum Engl Ed. 1998. 65:614–618.

12. Di Simone N, Meroni PL, de Papa N, Raschi E, Caliandro D, De Carolis CS, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum. 2000. 43:140–150.

13. Lojacono A, Spatola L, Faden D, Bettini P, Tanzi P, Balestrieri G, et al. Fetal stroke associated with maternal antiphospholipid antibodies: a case report. Lupus. 1996. 5:512.

14. Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol. 1998. 179:226–234.

15. Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum. 1995. 25:184–192.

16. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006. 54:899–907.

17. Qazi UM, Lam C, Karumanchi SA, Petri M. Soluble FMS-like tyrosine kinase is a significant predictor of preeclampsia in SLE pregnancy. Arthritis Rheum. 2006. 54:S264–S265.

18. Khamashta MA, Ruiz-Irastorza G, Hughes GR. Systemic lupus erythematosus flares during pregnancy. Rheum Dis Clin North Am. 1997. 23:15–30.

19. Buyon JP. Lahita RG, editor. Neonatal lupus syndromes. Systemic lupus erythematosus. 1999. 3rd ed. San Diego (CA): Academic Press;337–359.

20. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999. 341:1190–1196.

21. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003. 48:3207–3211.

22. Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol. 2006. 20:685–694.

23. Petty RE, Laxer RM. Cassidy JT, Petty RE, editors. Systemic lupus erythematosus. Textbook of pediatric rheumatology. 2005. 5th ed. Philadelphia (PA): WB Saunders Company;342–406.

24. Solomon BA, Laude TA, Shalita AR. Neonatal lupus erythematosus: discordant disease expression of U1RNP-positive antibodies in fraternal twins--is this a subset of neonatal lupus erythematosus or a new distinct syndrome? J Am Acad Dermatol. 1995. 32:858–862.

25. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum. 2001. 44:1832–1835.

26. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. 1999. 42:2335–2345.

27. Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003. 157:397–402.

28. Mintz G, Gutierrez G, Deleze M, Rodriguez E. Contraception with progestagens in systemic lupus erythematosus. Contraception. 1984. 30:29–38.

29. Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Guest F, editors. Contraceptive technology. 2004. 18th ed. New York (NY): Ardent Media.

30. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005. 353:2550–2558.

31. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001. 44:2350–2357.

32. Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 1992. 35:55–61.

33. Buyon JP, Kalunian KC, Ramsey-Goldman R, Petri MA, Lockshin MD, Ruiz-Irastorza G, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999. 8:677–684.

34. Clowse MEB, Magder LS, Petri M. Complement and double-stranded DNA antibodies predict pregnancy outcomes in lupus patients. Arthritis Rheum. 2004. 50:S408.

35. Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford). 2000. 39:1014–1019.

36. Cavallasca JA, Laborde HA, Ruda-Vega H, Nasswetter GG. Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE). Clin Rheumatol. 2008. 27:41–46.

37. Kim SH, Yoon BH, Park KH, Noh KR, Lee HS, Shin HC. Clinical sourse and pregnancy outcome in patients with systemic lupus erythematosus. Korean J Obstet Gynecol. 1996. 39:1607–1616.

38. Shin JH, Lee EY, Lee CK, Cho YS, Kim A, Yoo B, et al. Fetal outcome and clinical feature during pregnancy in systemic lupus erythematosus. Korean J Med. 2003. 65:511–519.

39. Ahn HY, Kim YH, Kil KC, Park IY, Lee G, Kim SJ, et al. Clinical course and obstetrical outcomes of 94 pregnancies in Korean patients with systemic lupus erythematosus (SLE). Korean J Obstet Gynecol. 2008. 51:147–157.